Your trusted source for investing success

Tag: abbott

BioSig Technologies Provides Shareholder Update

BioSig Technologies Provides Shareholder Update

BioSig Technologies, Inc. (OTCQB: BSGM), a medical device company developing the PURE EP(TM) System, a proprietary platform designed to address an unmet technology need for the $4 billion electrophysiology (EP) marketplace, today provided a shareholder update and highlighted the company’s recent achievements it has reached during the first part of

BioSig Technologies Completes Private Placement

BioSig Technologies Completes Private Placement

BioSig Technologies, Inc. (OTCQB: BSGM), a medical device company developing the PURE EP(TM) System, a proprietary platform designed to address an unmet technology need for the $4 billion electrophysiology (EP) marketplace, today announced the Company closed a private placement with proceeds of $4,349,953.50. Laidlaw & Co (UK) Ltd. in New

BioSig Technologies Announces Strategic Partnership with Mayo Clinic

BioSig Technologies Announces Strategic Partnership with Mayo Clinic

BioSig Technologies (OTCQB:BSGM), a medical device company developing the PURE EP(TM) System, a proprietary platform designed to address an unmet technology need for the $4 billion electrophysiology (EP) marketplace, today announced it has signed a ten-year strategic agreement with Mayo Clinic and Mayo Clinic Ventures. This new, expanded collaboration

Abbott offers EU concessions over $25 billion St. Jude deal

Reuters reported that Abbott Laboratories (NYSE:ABT) has offered concessions for its $25 billion bid for St. Jude Medical (NYSE:STJ).

As quoted in the article:
The move pushed back the European Commission’s decision on the deal to Nov. 21 from Nov. 9, according to a filing on the EU competition enforcer’s website on

The New Age of Glucose Monitoring

The New Age of Glucose Monitoring

From contact lenses that measure glucose levels to wireless sensors that read them through the skin, blood sugar monitoring is undergoing a major reinvention. But why are medical device companies investing so much into diabetes management specifically?

FenoLogica Biosciences Signs Licensing and Collaboration Agreement With the Pacific Northwest Research Institute

FenoLogica Biosciences Inc., a Seattle-WA-based life sciences company, announces completion of a licensing and collaboration agreement with the Pacific Northwest Research Institute (PNRI). FenoLogica also announces closing of its seed investment round that took place on June 13, 2016.

FenoLogica’s technology combines novel quantitative biology measurement techniques with cloud-based analytical tools

Enter Your Log In Credentials
×

Privacy & Legal Policy

Privacy Policy

×
Investing News Network